PMID- 28789440
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201001
IS  - 1792-1074 (Print)
IS  - 1792-1082 (Electronic)
IS  - 1792-1074 (Linking)
VI  - 14
IP  - 2
DP  - 2017 Aug
TI  - TRIM59 is a novel potential prognostic biomarker in patients with non-small cell 
      lung cancer: A research based on bioinformatics analysis.
PG  - 2153-2164
LID - 10.3892/ol.2017.6467 [doi]
AB  - Lung cancer is the leading cause of cancer-associated mortality worldwide and its 
      prognosis is poor. Few effective biomarkers for non-small cell lung cancer 
      (NSCLC) have been translated into the clinical practice aiming to assist in the 
      treatment plan design and prognosis evaluation. The aim of the present study was 
      to identify novel potential prognostic biomarkers for NSCLC. Tripartite motif 59 
      (TRIM59) was identified from a microarray dataset of matched-samples and was 
      verified as an aberrantly upregulated gene in NSCLC tissue. The expression level 
      of TRIM59 in NSCLC subtypes was observed to be significantly increased in large 
      cell lung carcinoma and squamous cell carcinoma as compared with that in 
      adenocarcinoma. Its expression correlated with several clinicopathological 
      features, including gender, smoking habits, and unfavorable tumor node and 
      pathological stages. Notably, TRIM59 demonstrated a negative correlation with 
      survival time and its overexpression indicated a poor prognosis in NSCLC. 
      Furthermore, univariate and multivariate Cox's regression analyses indicated that 
      TRIM59 was an independent prognostic factor in tumor tissue as compared with age, 
      gender, tumor stage, node stage, and metastasis. Gene set enrichment analysis and 
      protein-protein interaction network construction revealed that TRIM59 was 
      associated with oncogenic mammalian target of rapamycin (MTOR) and eukaryotic 
      initiation factor 4E (EIF4E) signaling through ubiquitin C binding. In 
      conclusion, it was revealed that TRIM59 is a novel prognostic biomarker 
      modulating oncogenic MTOR and EIF4E signaling pathways in NSCLC. These findings 
      provided a novel insight into the clinical application of TRIM59. Therefore, 
      TRIM59 may serve as an independent predictor for prognosis and a potential 
      therapeutic target for NSCLC.
FAU - Hao, Ling
AU  - Hao L
AD  - School of Basic Medical Sciences, Hubei University of Medicine, Shiyan, Hubei 
      442000, P.R. China.
FAU - Du, Boyu
AU  - Du B
AD  - School of Basic Medical Sciences, Hubei University of Medicine, Shiyan, Hubei 
      442000, P.R. China.
FAU - Xi, Xueyan
AU  - Xi X
AD  - School of Basic Medical Sciences, Hubei University of Medicine, Shiyan, Hubei 
      442000, P.R. China.
LA  - eng
PT  - Journal Article
DEP - 20170622
PL  - Greece
TA  - Oncol Lett
JT  - Oncology letters
JID - 101531236
PMC - PMC5530082
OTO - NOTNLM
OT  - Tripartite motif 59
OT  - biomarker
OT  - non-small cell lung cancer
OT  - prognostic value
EDAT- 2017/08/10 06:00
MHDA- 2017/08/10 06:01
PMCR- 2017/06/22
CRDT- 2017/08/10 06:00
PHST- 2016/12/08 00:00 [received]
PHST- 2017/06/14 00:00 [accepted]
PHST- 2017/08/10 06:00 [entrez]
PHST- 2017/08/10 06:00 [pubmed]
PHST- 2017/08/10 06:01 [medline]
PHST- 2017/06/22 00:00 [pmc-release]
AID - OL-0-0-6467 [pii]
AID - 10.3892/ol.2017.6467 [doi]
PST - ppublish
SO  - Oncol Lett. 2017 Aug;14(2):2153-2164. doi: 10.3892/ol.2017.6467. Epub 2017 Jun 
      22.